Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Methods and therapeutics to regulate hydrogen sulfide bioavailability
US11510925B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11510925-B2 |
| Application number | US-201916682209-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 13, 2019 |
| Priority date | Nov 13, 2018 |
| Publication date | Nov 29, 2022 |
| Grant date | Nov 29, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of cancer, cardiovascular disease, acute inflammation, chronic inflammation, and neurological disease.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutical composition comprising: a first therapeutic; and a second therapeutic; wherein the first therapeutic is one of an ATR kinase promotor and an ATR kinase inhibitor; and the first therapeutic is chemically distinct from the second therapeutic. 2. The pharmaceutical composition of claim 1 wherein the first therapeutic is the ATR kinase promotor. 3. The pharmaceutical composition of claim 1 wherein the first therapeutic is the ATR inhibitor. 4. The pharmaceutical composition of claim 1 wherein the second therapeutic is a H2S promotor. 5. The pharmaceutical composition of claim 1 wherein the second therapeutic is a H2S inhibitor. 6. The pharmaceutical composition of claim 1 wherein, the second therapeutic is a cystathionine beta-synthase (CBS) inhibitor. 7. The pharmaceutical composition of claim 1 wherein, the second therapeutic is a cystathionine gamma-lyase (CSE) inhibitor. 8. The pharmaceutical composition of claim 2 wherein the ATR kinase promotor is one of ETAA1 (Ewing's tumor-associated antigen 1) and TopBP1. 9. The pharmaceutical composition of claim 3 wherein the ATR kinase inhibitor is one of NU6027, AZD6738, BAY1895344, VX-803, and VX-970. 10. The pharmaceutical composition of claim 1 wherein the first therapeutic is the ATR kinase promotor and the second therapeutic is a H2S promotor. 11. The pharmaceutical composition of claim 10 wherein the ATR kinase promotor is ETAA1 (Ewing's tumor-associated antigen 1). 12. The pharmaceutical composition of claim 10 wherein the ATR kinase promotor is TopBP1. 13. The pharmaceutical composition of claim 1 wherein the first therapeutic is the ATR inhibitor and the second therapeutic is a H2S inhibitor. 14. The pharmaceutical composition of claim 13 wherein the ATR kinase inhibitor is NU6027. 15. The pharmaceutical composition of claim 13 wherein the ATR kinase inhibitor is AZD6738. 16. The pharmaceutical composition of claim 13 wherein the ATR kinase inhibitor is BAY1895344. 17. The pharmaceutical composition of claim 13 wherein the ATR kinase inhibitor is VX-803. 18. The pharmaceutical composition of claim 13 wherein the ATR kinase inhibitor is VX-970. 19. The pharmaceutical composition of claim 3 wherein the second therapeutic is one of cystathionine beta-synthase (CBS) inhibitor, a cystathionine gamma-lyase (CSE) inhibitor, and a combination of a CBS inhibitor and a CSE inhibitor. 20. The pharmaceutical composition of claim 3 wherein the ATR kinase inhibitor is one of NU6027, AZD6738, BAY1895344, VX-803, and VX-970. 21. The pharmaceutical composition of claim 3 wherein the second therapeutic is a combination of a cystathionine beta-synthase (CBS) inhibitor and a cystathionine gamma-lyase (CSE) inhibitor.
Assignees
Inventors
Classifications
Persulfides (thiuram disulfides A61K31/145; thiosulfonic acids A61K31/185) · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Nitriles; Isonitriles · CPC title
Sulfur, selenium or tellurium; Compounds thereof · CPC title
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11510925B2 cover?
- The presently claimed invention is related to compositions and methods for treating H2S related diseases comprising administering a pharmacologically effective amount of pharmaceutical composition containing a first therapeutic, wherein the first therapeutic includes one of an ATR kinase inhibitor and an ATR kinase promotor. According to further embodiments the H2S related disease is one of can…
- Who is the assignee on this patent?
- Univ Louisiana State, Board Of Supervisors Of Louisiana State Univ
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).